Drug intelligence / Profile preview

meropenem + piperacillin-tazobactam + ticarcillin-clavulanate

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Intravenous
01

Overview

This is a combination regimen of three broad-spectrum beta-lactam antibiotics, each with distinct but overlapping spectra of activity. - **Meropenem** is a carbapenem antibiotic with very broad-spectrum activity against gram-positive, gram-negative, and anaerobic bacteria. It is highly effective against many resistant organisms, including extended-spectrum beta-lactamase (ESBL) producers and Pseudomonas aeruginosa[4][6]. - **Piperacillin-tazobactam** combines an antipseudomonal penicillin with the beta-lactamase inhibitor tazobactam to extend its spectrum to include many beta-lactamase-producing organisms and anaerobes[3][6]. - **Ticarcillin-clavulanate** pairs another antipseudomonal penicillin with clavulanic acid, also a beta-lactamase inhibitor, providing similar coverage for resistant gram-negatives and anaerobic bacteria[2][3][6]. These agents are used in severe or high-risk infections where multidrug-resistant organisms are suspected or confirmed—such as complicated intra-abdominal infections or hospital-acquired pneumonia—though their combined use together as a single regimen is not standard clinical practice due to overlapping spectra and increased risk of toxicity/resistance. Each component acts by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins; the inhibitors block destruction by bacterial beta-lactamases.

Brand names
MerremZosynTimentin
02

Targets

NeuraminidasePBP (Penicillin-binding protein family)β-lactamaseLdt (L,D-transpeptidase)

Beyond the preview

Go deeper on meropenem + piperacillin-tazobactam + ticarcillin-clavulanate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on meropenem + piperacillin-tazobactam + ticarcillin-clavulanate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call